Skip to main content
. 2018 Sep 6;3(17):e120994. doi: 10.1172/jci.insight.120994

Figure 1. Altered proteome in BALF from never-smokers, asymptomatic smokers, and chronic obstructive pulmonary disease (COPD) patients.

Figure 1

(A) Number of proteins identified in BALF in each sample group, never-smokers (n = 5), smokers (n = 12), and COPD (n = 42); data presented as medians ± IQR. (B) Principal component analysis. (C) Absolute quantification with isotopically labeled peptides by mass spectrometry, n = 5–42; data presented as medians ±IQR, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, Kruskal-Wallis and Dunn’s multiple comparisons test. (D) Ratio of MUC5AC to MUC5B calculated from absolute quantification data in C, n = 5–42 patients/group; data presented as medians ± IQR, **P ≤ 0.01, Kruskal-Wallis and Dunn’s multiple comparisons test. AGR2, anterior gradient protein 2; DMBT1, deleted in malignant brain tumors 1; FCGBP, Fc fragment of IgG binding protein; PSCA, prostate stem cell antigen; TFF3, trefoil factor 3; TGM2, transglutaminase-2; ZG16B, zymogen granule protein 16 B.